Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HPRT1 | P00492 | 5/20 | 0.42 |
| ▸ | PNP | P00491 | 3/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3859183 | 1.00 | CDK1 (0.49) | CDK1CCNB1CCNE1CDK2FGFR1 | |
| SCHEMBL3942848 | 0.90 | HSP90AB1 (0.44) | FGFR1SLC22A6PNPHSP90AA1HSP90AB1 | |
| SCHEMBL3942827 | 0.90 | HSP90AB1 (0.44) | FGFR1SLC22A6PNPHSP90AA1HSP90AB1 | |
| SCHEMBL3856913 | 0.88 | FGFR1 (0.48) | CDK1CCNB1CCNE1CDK2FGFR1 | |
| Pmedap SCHEMBL29571667 | 0.80 | FGFR1 (0.72) | CDK1CCNB1CCNE1CDK2FGFR1 | |
| Pmedap SCHEMBL215611 | 0.80 | FGFR1 (0.72) | CDK1CCNB1CCNE1CDK2FGFR1 | |
| SCHEMBL3850969 | 0.79 | CYP3A4 (0.52) | CDK1CCNB1CCNE1CDK2FGFR1 | |
| SCHEMBL3858651 | 0.79 | CYP3A4 (0.52) | CDK1CCNB1CCNE1CDK2FGFR1 | |
| SCHEMBL3850956 | 0.79 | CYP3A4 (0.52) | CDK1CCNB1CCNE1CDK2FGFR1 | |
| SCHEMBL3861087 | 0.78 | CDK1 (0.49) | CDK1CCNB1CCNE1CDK2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20060252729-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2006-11-09 | — | — | US | disclosed |
| EP-1656387-A2 | NUCLEOBASE PHOSPHONATE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005012324-A2 | NUCLEOBASE PHOSPHONATE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252729-A1 | Nucleobase phosphonate analogs for antiviral treatment | TYMP, TK1, NUDT1 | CDK1 359/4885CCNB1 430/4885CCNE1 522/4885 |
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | TYMP, TK1, NUDT1 | CDK1 359/4885CCNB1 430/4885CCNE1 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.